Alector, Inc. (ALEC): Cash & Equivalents
$65.80M
As of 2025-12-31
$59.91M
As of 2026-06-30
-24.7%
3-year compound annual growth
+5.7%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $65.80M | +99.3% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $33.02M | -55.7% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $74.56M | -51.7% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $154.32M | -53.1% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $329.15M | +558.7% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $49.97M | -44.3% | 2023-02-28, Balance as of period end |
| 2019-12-31 | $89.64M | +36.9% | 2022-02-24, Balance as of period end |
| 2018-12-31 | $65.47M | +101.8% | 2021-02-25, Balance as of period end |
| 2017-12-31 | $32.45M | n/a | 2020-03-24, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Alector, Inc. (ALEC) | 2025-12-31 | $65.80M | +99.3% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $25.18M | +24.9% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $41.72M | +52.3% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $17.97M | n/m |
| Relay Therapeutics, Inc. (RLAY) | 2025-12-31 | $84.02M | -32.4% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $4.96M | +51.4% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $40.79M | -10.9% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $110.82M | +29.0% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $217.05M | +289.7% |
Compare ALEC, LENZ, MGX, PTHS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗